{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:12:10Z","timestamp":1786983130792,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/27\/B\/NZ5\/01440"],"award-info":[{"award-number":["2017\/27\/B\/NZ5\/01440"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Murine models of human diseases are of outmost importance for both studying molecular mechanisms driving their development and testing new treatment strategies. In this review, we first discuss the etiology and risk factors for autoimmune liver disease, including primary biliary cholangitis, autoimmune hepatitis and primary sclerosing cholangitis. Second, we highlight important features of murine transgenic models that make them useful for basic scientists, drug developers and clinical researchers. Next, a brief description of each disease is followed by the characterization of selected animal models.<\/jats:p>","DOI":"10.1007\/s43440-021-00351-y","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:03:00Z","timestamp":1642212180000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Selected transgenic murine models of human autoimmune liver diseases"],"prefix":"10.1007","volume":"74","author":[{"given":"Katarzyna","family":"Trzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pydyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Jura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Kotlinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"351_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369\u201395.","journal-title":"J Intern Med"},{"key":"351_CR2","unstructured":"The National Stem Cell Foundation \u2013 Home. https:\/\/nationalstemcellfoundation.org\/. Accessed 24 Nov 2021"},{"key":"351_CR3","unstructured":"The Autoimmune Registry. https:\/\/www.autoimmuneregistry.org\/. Accessed 24 Nov 2021"},{"key":"351_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00163","author":"U Christen","year":"2018","unstructured":"Christen U, Hintermann E. Autoantibodies in autoimmune hepatitis: Can epitopes tell us about the etiology of the disease? Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00163.","journal-title":"Front Immunol"},{"key":"351_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/312817","author":"HI Fallatah","year":"2012","unstructured":"Fallatah HI, Akbar HO. Autoimmune hepatitis as a unique form of an autoimmune liver disease: Immunological aspects and clinical overview. Autoimmune Dis. 2012. https:\/\/doi.org\/10.1155\/2012\/312817.","journal-title":"Autoimmune Dis"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/J.JAUT.2018.10.004","volume":"95","author":"B Terziroli Beretta-Piccoli","year":"2018","unstructured":"Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: a comprehensive overview. J Autoimmun. 2018;95:144\u201358. https:\/\/doi.org\/10.1016\/J.JAUT.2018.10.004.","journal-title":"J Autoimmun"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031114","volume":"22","author":"A Youness","year":"2021","unstructured":"Youness A, Miquel CH, Gu\u00e9ry JC. Escape from x chromosome inactivation and the female predominance in autoimmune diseases. Int J Mol Sci. 2021;22:1\u201312.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"351_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","volume":"28","author":"J Petrovi\u0107","year":"2019","unstructured":"Petrovi\u0107 J, Pe\u0161i\u0107 V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2019;28(1):88\u201394. https:\/\/doi.org\/10.1038\/s41431-019-0480-8.","journal-title":"Eur J Hum Genet"},{"key":"351_CR9","unstructured":"Autoimmune diseases | Office on Women\u2019s Health. https:\/\/www.womenshealth.gov\/a-z-topics\/autoimmune-diseases. Accessed 24 Nov 2021"},{"key":"351_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","volume":"11","author":"A Lleo","year":"2017","unstructured":"Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hep Intl. 2017;11:485\u201399.","journal-title":"Hep Intl"},{"key":"351_CR11","doi-asserted-by":"publisher","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","volume":"7","author":"T Purohit","year":"2015","unstructured":"Purohit T, Cappell MS. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7:926\u201341. https:\/\/doi.org\/10.4254\/wjh.v7.i7.926.","journal-title":"World J Hepatol"},{"key":"351_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"EJ Carey","year":"2015","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. The Lancet. 2015;386:1565\u201375.","journal-title":"The Lancet"},{"key":"351_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/s-0034-1383725","volume":"34","author":"I Bianchi","year":"2014","unstructured":"Bianchi I, Carbone M, Lleo A, Invernizzi P. Genetics and epigenetics of primary biliary cirrhosis. Semin Liver Dis. 2014;34:255\u201364. https:\/\/doi.org\/10.1055\/s-0034-1383725.","journal-title":"Semin Liver Dis"},{"key":"351_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/S-0034-1383726","volume":"34","author":"BD Juran","year":"2014","unstructured":"Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014;34:265. https:\/\/doi.org\/10.1055\/S-0034-1383726.","journal-title":"Semin Liver Dis"},{"key":"351_CR15","doi-asserted-by":"crossref","unstructured":"Probert PM, Leitch AC, Dunn MP, et al. Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis. J Hepatol. 2018;69(5):1123\u20131135","DOI":"10.1016\/j.jhep.2018.06.027"},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","volume":"13","author":"C Leung","year":"2016","unstructured":"Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412\u201325.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"351_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2015-311004.","journal-title":"Gut"},{"key":"351_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nri.2016.42","volume":"16","author":"MG Rooks","year":"2016","unstructured":"Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16:341\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"351_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/jcm9030754","volume":"9","author":"C Vl\u0103du\u0163","year":"2020","unstructured":"Vl\u0103du\u0163 C, Cioc\u00eerlan M, Bilous D, et al. An overview on primary sclerosing cholangitis. J Clin Med. 2020;9(3):754.","journal-title":"J Clin Med"},{"key":"351_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","volume":"67","author":"R Tang","year":"2018","unstructured":"Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67:534\u201371. https:\/\/doi.org\/10.1136\/gutjnl-2016-313332.","journal-title":"Gut"},{"key":"351_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","volume":"69","author":"Y Wei","year":"2020","unstructured":"Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020;69:569\u201377. https:\/\/doi.org\/10.1136\/gutjnl-2018-317836.","journal-title":"Gut"},{"key":"351_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jhep.2010.02.019","volume":"53","author":"C Corpechot","year":"2010","unstructured":"Corpechot C, Chr\u00e9tien Y, Chazouill\u00e8res O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2010.02.019.","journal-title":"J Hepatol"},{"key":"351_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.20907","volume":"42","author":"ME Gershwin","year":"2005","unstructured":"Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194\u2013202. https:\/\/doi.org\/10.1002\/hep.20907.","journal-title":"Hepatology"},{"key":"351_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cld.798","volume":"14","author":"C Lammert","year":"2019","unstructured":"Lammert C. Genetic and environmental risk factors for autoimmune hepatitis. Clin Liver Dis. 2019;14:29\u201332.","journal-title":"Clin Liver Dis"},{"key":"351_CR25","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol. 2017;67:1298\u2013323.","journal-title":"J Hepatol"},{"key":"351_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/J.BBADIS.2018.07.025","volume":"1865","author":"V Mariotti","year":"2019","unstructured":"Mariotti V, Cadamuro M, Spirli C, et al. Animal models of cholestasis: an update on inflammatory cholangiopathies. Biochimica et Biophysica Acta (BBA). 2019;1865:954\u201364. https:\/\/doi.org\/10.1016\/J.BBADIS.2018.07.025.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"351_CR27","first-page":"970","volume":"1865","author":"U Christen","year":"2019","unstructured":"Christen U. Animal models of autoimmune hepatitis. Biochem Biophys Acta. 2019;1865:970\u201381.","journal-title":"Biochem Biophys Acta"},{"key":"351_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","volume":"64","author":"GJ Webb","year":"2015","unstructured":"Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: a comprehensive review. J Autoimmun. 2015;64:42\u201352.","journal-title":"J Autoimmun"},{"issue":"2","key":"351_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, Mcdonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379(2):103\u201312.","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"351_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22736","volume":"49","author":"A Lleo","year":"2009","unstructured":"Lleo A, Selmi C, Invernizzi P, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871\u20139. https:\/\/doi.org\/10.1002\/hep.22736.","journal-title":"Hepatology"},{"key":"351_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000551.PUB3","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012. https:\/\/doi.org\/10.1002\/14651858.CD000551.PUB3.","journal-title":"Cochrane Database Syst Rev"},{"key":"351_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715\u201320. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029.","journal-title":"Gastroenterology"},{"key":"351_CR33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.4049\/JIMMUNOL.177.3.1655","volume":"177","author":"S Oertelt","year":"2006","unstructured":"Oertelt S, Lian Z-X, Cheng C-M, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-\u03b2 receptor II dominant-negative mice. J Immunol. 2006;177:1655\u201360. https:\/\/doi.org\/10.4049\/JIMMUNOL.177.3.1655.","journal-title":"J Immunol"},{"key":"351_CR34","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/HEP.21385","volume":"44","author":"K Wakabayashi","year":"2006","unstructured":"Wakabayashi K, Lian ZX, Moritoki Y, et al. IL-2 receptor \u03b1\u2212\/\u2212 mice and the development of primary biliary cirrhosis. Hepatology. 2006;44:1240\u20139. https:\/\/doi.org\/10.1002\/HEP.21385.","journal-title":"Hepatology"},{"key":"351_CR35","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1053\/j.gastro.2008.02.020","volume":"134","author":"JT Salas","year":"2008","unstructured":"Salas JT, Banales JM, Sarvide S, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134:1482\u201393. https:\/\/doi.org\/10.1053\/j.gastro.2008.02.020.","journal-title":"Gastroenterology"},{"key":"351_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28641\/suppinfo","author":"HR Bae","year":"2016","unstructured":"Bae HR, Leung PSC, Tsuneyama K, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology. 2016. https:\/\/doi.org\/10.1002\/hep.28641\/suppinfo.","journal-title":"Hepatology"},{"key":"351_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166086","author":"J Kotlinowski","year":"2021","unstructured":"Kotlinowski J, Hutsch T, Czyzynska-Cichon I, et al. Deletion of Mcpip1 in Mcpip1fl\/flAlbCre mice recapitulates the phenotype of human primary biliary cholangitis. Biochem Biophys Acta. 2021. https:\/\/doi.org\/10.1016\/j.bbadis.2021.166086.","journal-title":"Biochem Biophys Acta"},{"key":"351_CR38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7354","author":"A Shahid","year":"2020","unstructured":"Shahid A, Punshi A, Ahmed Khan B, et al. Type 2 autoimmune hepatitis in a male patient with a rare complication of vasculitis. Cureus. 2020. https:\/\/doi.org\/10.7759\/cureus.7354.","journal-title":"Cureus"},{"key":"351_CR39","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.20109","volume":"39","author":"P Lapierre","year":"2004","unstructured":"Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology. 2004;39:1066\u201374. https:\/\/doi.org\/10.1002\/hep.20109.","journal-title":"Hepatology"},{"key":"351_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15682","author":"E Gadour","year":"2021","unstructured":"Gadour E. Autoimmune hepatitis: treatment options and management review. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.15682.","journal-title":"Cureus"},{"key":"351_CR41","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","volume":"135","author":"M Kido","year":"2008","unstructured":"Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008;135:1333\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.042.","journal-title":"Gastroenterology"},{"key":"351_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066604","author":"N Qi","year":"2013","unstructured":"Qi N, Liu P, Zhang Y, et al. Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking Tyro3, Axl and mer receptor tyrosine kinases. PLoS\u00a0One. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0066604.","journal-title":"PLoS\u00a0One"},{"key":"351_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3930750","author":"B Zhao","year":"2018","unstructured":"Zhao B, Chang L, Fu H, et al. The role of autoimmune regulator (AIRE) in peripheral tolerance. J Immunol Res. 2018. https:\/\/doi.org\/10.1155\/2018\/3930750.","journal-title":"J Immunol Res"},{"key":"351_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27639\/suppinfo","author":"M Hardtke-Wolenski","year":"2014","unstructured":"Hardtke-Wolenski M, Taubert R, Noyan F, et al. Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens. Hepatology. 2014. https:\/\/doi.org\/10.1002\/hep.27639\/suppinfo.","journal-title":"Hepatology"},{"key":"351_CR45","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jhep.2008.01.020","volume":"48","author":"TJ Weism\u00fcller","year":"2008","unstructured":"Weism\u00fcller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis\u2014Aetiopathogenesis, autoimm. J Hepatol. 2008;48:S38\u201357.","journal-title":"J Hepatol"},{"key":"351_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","volume":"127","author":"P Fickert","year":"2004","unstructured":"Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127:261\u201374. https:\/\/doi.org\/10.1053\/j.gastro.2004.04.009.","journal-title":"Gastroenterology"},{"key":"351_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90148-8","author":"SH Cheng","year":"1990","unstructured":"Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the of most cystic fibrosis k\/lolecular basis. Cell. 1990. https:\/\/doi.org\/10.1016\/0092-8674(90)90148-8.","journal-title":"Cell"},{"key":"351_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63234-8","author":"PR Durie","year":"2004","unstructured":"Durie PR, Kent G, James Phillips M, Ackerley CA. Animal model characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol. 2004. https:\/\/doi.org\/10.1016\/S0002-9440(10)63234-8.","journal-title":"Am J Pathol"},{"key":"351_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/path.1257","volume":"199","author":"L Libbrecht","year":"2003","unstructured":"Libbrecht L, Meerman L, Kuipers F, et al. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol. 2003;199:191\u2013200. https:\/\/doi.org\/10.1002\/path.1257.","journal-title":"J Pathol"},{"key":"351_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","volume":"17","author":"CHC Leenaars","year":"2019","unstructured":"Leenaars CHC, Kouwenaar C, Stafleu FR, et al. Animal to human translation: a systematic scoping review of reported concordance rates. J Transl Med. 2019;17:223. https:\/\/doi.org\/10.1186\/s12967-019-1976-2.","journal-title":"J Transl Med"},{"key":"351_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/BIOINFORMATICS\/BTU611","volume":"31","author":"K Rhrissorrakrai","year":"2015","unstructured":"Rhrissorrakrai K, Belcastro V, Bilal E, et al. Understanding the limits of animal models as predictors of human biology: lessons learned from the sbv IMPROVER Species Translation Challenge. Bioinformatics (Oxford, England). 2015;31:471\u201383. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTU611.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"351_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjos-2019-100041","volume":"4","author":"P Pound","year":"2020","unstructured":"Pound P, Ram R. Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers. BMJ Open Sci. 2020;4: 100041. https:\/\/doi.org\/10.1136\/bmjos-2019-100041.","journal-title":"BMJ Open Sci"},{"key":"351_CR53","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1073\/PNAS.0800387105","volume":"105","author":"BY Liao","year":"2008","unstructured":"Liao BY, Zhang J. Null mutations in human and mouse orthologs frequently result in different phenotypes. Proc Natl Acad Sci. 2008;105:6987\u201392. https:\/\/doi.org\/10.1073\/PNAS.0800387105.","journal-title":"Proc Natl Acad Sci"},{"key":"351_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ng2047","author":"DT Odom","year":"2007","unstructured":"Odom DT, Dowell RD, Jacobsen ES, et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat Genetics. 2007. https:\/\/doi.org\/10.1038\/ng2047.","journal-title":"Nat Genetics"},{"key":"351_CR55","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005639","volume":"45","author":"FR Sharp","year":"2014","unstructured":"Sharp FR, Jickling GC. Modelling immunity and inflammation in stroke: Differences between rodents and humans? Stroke. 2014;45: e179. https:\/\/doi.org\/10.1161\/STROKEAHA.114.005639.","journal-title":"Stroke"},{"key":"351_CR56","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s12276-020-0473-2","volume":"52","author":"JC Park","year":"2020","unstructured":"Park JC, Im S-H. Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. Exp Mol Med. 2020;52:1383\u201396. https:\/\/doi.org\/10.1038\/s12276-020-0473-2.","journal-title":"Exp Mol Med"},{"key":"351_CR57","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature17655","volume":"532","author":"LK Beura","year":"2016","unstructured":"Beura LK, Hamilton SE, Bi K, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature. 2016;532:512\u20136. https:\/\/doi.org\/10.1038\/nature17655 (532:7600).","journal-title":"Nature"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00351-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T04:20:11Z","timestamp":1648527611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00351-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00351-y","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}